Macquarie Group’s Acceleron Pharma XLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,683
Closed -$290K 2679
2021
Q3
$290K Hold
1,683
﹤0.01% 1750
2021
Q2
$211K Hold
1,683
﹤0.01% 1795
2021
Q1
$228K Sell
1,683
-468
-22% -$60.5K ﹤0.01% 1674
2020
Q4
$275K Buy
2,151
+900
+72% +$106K ﹤0.01% 1582
2020
Q3
$141K Sell
1,251
-534
-30% -$53.2K ﹤0.01% 1697
2020
Q2
$170K Buy
1,785
+854
+92% +$82.3K ﹤0.01% 1600
2020
Q1
$84K Sell
931
-969
-51% -$75.3K ﹤0.01% 1685
2019
Q4
$101K Buy
+1,900
New +$86.6K ﹤0.01% 1776
2018
Q4
Sell
-100
Closed -$6K 2391
2018
Q3
$6K Sell
100
-700
-88% -$34.4K ﹤0.01% 2056
2018
Q2
$39K Buy
+800
New +$29.1K ﹤0.01% 1982

Macquarie Group's XLRN Position: Q4 2021 in Review

Macquarie Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,683 shares — an estimated $290K sold.

Macquarie Group first reported a position in XLRN in Q2 2018 and held it in 10 quarters. The position peaked at $290K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Macquarie Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Macquarie Group sold 1,683 Acceleron Pharma shares in Q4 2021, an estimated $290K.
  • Macquarie Group first reported a position in Acceleron Pharma in Q2 2018 and held it in 10 quarters.
  • Macquarie Group's Acceleron Pharma position peaked at $290K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Macquarie Group's 13F filing for Q4 2021, filed 11 Feb 2022.